We established three lymphoblastoid cell lines from a bullous pemphigoid (BP) patient's peripheral blood by means of EBV transformation, which produced human monoclonal anti-basement membrane zone (BMZ) IgG antibodies. A blocking immunofluorescence test using these MAbs, designated 5A, 5E, and lOD, revealed that 5A and 5E recognized the same or a closely associated epitope, but the epitope for 1OD was completely different. 18 of 30 BP sera blocked the reactivity of lOD MAb and 17 sera blocked 5E, while 9 sera did not block the staining of either antibody. Immunoblot analysis demonstrated that both 5A 
Introduction
Bullous pemphigoid (BP)' is an autoimmune skin disease characterized by tense blister formation at the dermoepidermal junction (1) . The direct immunofluorescence test reveals IgG deposits along the basement membrane zone (BMZ; 2). In most cases circulating anti-BMZ antibodies are also detected by the indirect immunofluorescence (IIF) technique (3) . It has recently been reported that anti-BMZ autoantibodies in the 1 . Abbreviations used in this paper: BMZ, basement membrane zone; BP, bullous pemphigoid; IIF, indirect immunofluorescence; TBS, Tris (hydroxymethyl) aminomethane hydrochloride-buffered saline. sera from BP patients play important roles in its pathogenesis (4) (5) (6) (7) (8) . Furthermore, some investigators have suggested the heterogeneity of the antibodies (9) (10) (11) (12) (13) (14) (15) , while others have implied that BP antibody recognizes a single unique antigen (16) (17) (18) (19) (20) (21) .
Recently, production of human MAbs using EBV transformation (22-27) or hybridoma techniques (28-32) has made a marked advance, and it has contributed to the progress in various fields of research, although this approach has not been applied to autoimmune blistering diseases such as BP and pemphigus. In this study we have tried to elaborate human monoclonal anti-BMZ antibodies by EBV transformation and to examine the heterogeneity of the anti-BMZ antibodies in BP sera.
Methods
Patients and sera. Peripheral blood lymphocytes were obtained from a 72-yr-old male BP patient having anti-BMZ antibodies in the sera at a titer of 320. Sera for blocking immunofluorescence and Western blot experiments were obtained from 30 confirmed BP patients possessing circulating antibodies at titers of 560 by IIF test.
IIF. IIF was performed according to the previously established method (2, 3) using normal human skin section as a substrate. All of FITC-conjugated anti-human IgG ('y-chains), IgM (A-chains), IgA (achains), and IgE (e-chains) rabbit antisera were purchased from DAKO, Copenhagen, Denmark, and used at a dilution of 1:10-1:20.
Lymphocyte preparation. (33) . The supernatant containing EBV was harvested, filtered through a 0.45-Am filter (Millipore Japan, Yamagata, Japan), and stored at -700C. Peripheral blood lymphocytes prepared as previously mentioned were incubated with 1 ml ofsupematant containing EBV for 2 h at 37°C with occasional swirling. After incubation the cells were washed three times with PBS, resuspended in 20 ml RPMI 1640 with 20% FCS and penicillin/streptomycin, and 0.2 ml of suspended medium was seeded in each well of a 96-well culture plate (Falcon Plastics, Cockeysville, MD). The plate was placed in a 5% CO2 humidified atmosphere, and half ofthe medium was changed every fourth day until colonies grew enough for screening assay.
Screening assay. Supernatants from wells with colony formation were screened for anti-BMZ antibodies by IIF, using FITC-conjugated anti-human IgG antiserum as a second antibody.
Cloning. The transformants producing anti-BMZ antibodies were cloned in 96-well plates by a limiting dilution method on feeder layers of cord blood lymphocytes that had been previously treated with 20 ,ug/ml mitomycin C (Kyowa Hakko, Tokyo, Japan) for 30 min. Supematants from wells with growing colonies were again tested by IIF for the presence of anti-BMZ antibodies.
Study for IgG subclasses. IgG subclasses of the antibodies were determined by IIF using anti-human IgG subclass mouse MAbs as previously described (34) .
Biotinylation of the antibodies. Cloned lymphoblastoid cell lines were cultured with serum-free medium, S-clone SF-B (Sankou Junyaku, Tokyo, Japan). IgG was prepared from the supernatant by salt precipitation with 50% saturated ammonium sulphate. Biotinylation of IgG was performed according to the previously reported method (35) .
Blocking immunofluorescence experiments. To characterize the epitopes recognized by the human MAbs, a blocking immunofluorescence test was performed according to the previously described method with minor modifications (I 1, 36). Normal human skin sections were pretreated with IgG solution purified from culture supernatant containing anti-BMZ MAbs or with the diluted sera from BP patients or normal controls for 30 min at 37°C, and subsequently incubated with diluted biotin-conjugated human MAbs for 30 min at 37°C, followed by incubation with 1:1,000 diluted FITC-conjugated egg white avidin (Tago Inc., Burlingame, CA) for 30 min at room temperature. Between each treatment the sections were rinsed for 15 min with three changes ofcooled PBS. The preparations were observed by epifluorescence microscope (BH2-RFL; Olympus, Tokyo, Japan).
Immunoblot analysis. Immunoblotting was performed mainly according to the method described by Labib et al. (15) . Adult foreskin was obtained at circumcision surgery. Skin pieces prepared by forceps and scissors were incubated in PBS containing 2 mM EDTA (Nakarai Tesque, Kyoto, Japan) and 2 mM PMSF (Sigma Chemical Co., St. Louis, MO) for 2 d at 4°C, and epidermis was peeled off by forceps as previously reported (37) . This epidermis preparation was confirmed to retain BP antigen by IIF. The pieces of epidermis were collected and homogenized by glass homogenizer in an ice-water bath with 1% SDS, 0.01 M Tris (hydroxymethyl) aminomethane hydrochloride buffer (Nakarai Tesque) supplemented with 2 mM EDTA, 2 mM PMSF, 5 mg/liter each of four proteinase inhibitors (leupeptin, antipain, chymostatin, and pepstatin A; Sigma Chemical Co.), and 5% ,8-mercaptoethanol (Kanto Chemical Co., Tokyo, Japan), pH 6.8. The homogenized sample was boiled for 5 min and centrifuged. Supernatant was harvested and stored at -70°C as aliquots. SDS-PAGE was performed by Laemmli's method (38) using 6% separating gel. Separated proteins were electrophoretically transferred to a nitrocellulose sheet (Schleicher and Schuell, Dassel, FRG; 39). For immunostaining, strips of blotted sheet were first blocked by 3% skimmed milk (Morinaga, Tokyo, Japan) in Tris (hydroxymethyl) aminomethane hydrochloride buffered saline (TBS) for 2 h at room temperature. Blocked strips were treated with MAbs or sera from BP patients or normal individuals diluted with 3% skimmed milk overnight at 4°C. Subsequently the strips were reacted with peroxidase-conjugated anti-human IgG (ychains) rabbit antiserum (DAKO) diluted at 1:100 with 3% skimmed milk in TBS for 2 h. Between each treatment the strips were washed for 15 min with three changes of TBS containing 0.5% Tween 20 (Sigma Chemical Co.). Finally, color was developed by 4-chloro-1-naphthol (Bio-Rad Laboratories, Richmond, CA) in the presence of hydrogen peroxide.
Protein measurement and IgG purification from BP sera. Total protein was determined by the method of Lowry et al. (40) using BSA as a standard. IgG fractions were isolated from several BP sera by salt precipitation with 50% saturated ammonium sulphate, followed by protein A-Sepharose CL-4B (Pharmacia AB, Uppsala, Sweden) affinity chromatography (41) . The eluate was dialyzed against PBS containing 0.1% NaN3 and concentrated on a concentrator (Centriprep 10;
Amicon Corp., Danvers, MA).
Results
Establishment oflymphoblastoid cell lines. B lymphocytes infected with EBV were cultured for 3 wk in a 96-well plate. Most wells showed colony formation. Screening test demonstrated that six wells were positive for anti-BMZ antibodies. Three were not stable and the production of antibody decreased rapidly. The remaining three wells (designated 5A, 5E, and lOD) were cloned by the limiting dilution method. Each clone was again confirmed by IIF to produce anti-BMZ IgG antibody ( Fig. 1) , but no IgM, IgA, or IgE antibodies were found. All wells with colony formation showed the presence of anti-BMZ antibodies, which suggested that monoclonality of the antibodies had been almost achieved in the initial cultures. These cell lines continued to produce antibodies for more than 6 mo until cells were frozen to be stored. The IgG subclass was analyzed for three clones and for the serum from the donor BP patient. All three human MAbs were IgG2, while the serum of the donor contained IgGl, IgG2, and IgG4, but not IgG3, autoantibodies.
IgG isolation from the supernatant of lymphoblastoid cell cultures and biotinylation. Total protein concentration and the terminal dilution point for IIF were determined for each ofthe IgG fractions prepared from the culture supernatant of lymphoblastoid cells and the biotin conjugate. Total protein concentrations in undiluted solutions and the terminal dilution points, respectively, were as follows: 6 mg/ml and 1:640 for SA IgG; 12 mg/ml and 1:2,560 for SE IgG; 1.2 mg/ml and 1:160 for lOD IgG; 6 mg/ml and 1:160 for biotinylated SA; 10 mg/ml and 1:640 for biotinylated SE; and 1.5 mg/ml and 1:40 for biotinylated lOD. To correspond to the titers of BP sera and make a comparison easier, dilution instead of protein concentration was used for these solutions in the following experiments.
Blocking immunofluorescence experiments. For this test, examined by immunoblotting as shown in Table I . 22 sera reacted strongly with the same 230-kD protein band. In addition, 12 sera specifically stained a protein band of -170 kD. 10 sera yielded both 230-and 170-kD bands, 12 sera showed only a 230-kD band and 2 sera showed only a 170-kD band. Six BP sera did not react with either protein band. None of 18 normal sera showed reactivity with either band. No specific correlation between the results of blocking immunofluorescence and immunoblotting was observed in this table.
Because 5E MAb reacted with the 230-kD protein, we studied the relationship between the blocking effect on 5E reactivity and the staining of the 230-kD band on immunoblotting of individual BP serum (Table II) . 14 of 30 BP sera showed both the blocking effect on 5E and staining of the 230-kD band. Three sera showed a clear blocking effect on SE, although they did not stain the 230-kD band on immunoblotting. Furthermore, eight sera that stained the 230-kD band did not block SE reactivity. Five sera did not show either the blocking effect or staining.
Discussion
We established three individual lymphoblastoid cell lines that continued to produce human monoclonal anti-BMZ IgG antibodies for more than 6 mo. That all cloned wells with colony formation contained anti-BMZ antibodies in the supernatant safely confirmed the monoclonality of these antibodies. This was further substantiated by the fact that immunoblot analysis showed a single positive band reacted with 5A and SE antibodies. The IgG subclass study revealed that all of our antibodies were of the IgG2 subclass. It remains unknown why only IgG2-producing B cells were preferentially transformed, despite the fact that the patient's serum contained IgGl, IgG2, and IgG4 anti-BMZ antibodies.
There The accuracy of the blocking immunofluorescence test used in this study is supported by three observations: (a) the reactivity of each biotinylated antibody was blocked by the corresponding IgG fraction; (b) the reactivities of SA and SE MAbs were blocked by each other; and (c) the majority of BP sera were able to block the reactivity ofall MAbs, in contrast to the absence of such an effect with any of the normal sera. These results suggested that the blocking effect was due to the presence of IgG reacting with the same epitope. Nevertheless, several discrepancies existed between the results of blocking immunofluorescence and Western blot experiments for 5E MAb. Although 14 of 30 BP sera showed both blocking effect and reactivity with the 230-kD protein, and 5 BP sera did not show either, 8 BP sera that recognized the 230-kD protein on immunoblotting did not block 5E antibody. This may be because these sera contained antibodies reacting with epitope(s) of the 230-kD protein different from that recognized by SE antibody. Another discrepancy was that three sera that were able to block the reactivity of SE antibodies did not bind to the 230-kD antigen on immunoblotting using anti-human IgG antiserum as a second antibody. There may be several possible explanations for this: (a) unknown substances that nonspecifically destroy antigenic sites in BMZ, such as proteinases, are present in some of BP sera but not in normal sera; (b) these sera possess Ig other than IgG reacting with the same epitope for 5E antibody; and (c) these sera bind to an epitope on the 230-kD molecule near enough to the SE epitope to block the latter by steric hindrance, but the former is destroyed by denaturation for immunoblotting, whereas the SE epitope is not. To solve this issue, immunoblotting was performed using peroxidase-conjugated anti-human IgM, IgA, and IgE antisera as second antibodies. This study revealed that three sera possessed both IgM and IgE types ofIg, which clearly reacted with the 230-kD protein (data not shown). Furthermore, IgG fractions purified from these sera by protein A chromatography did not show blocking effects on SE reactivity by blocking immunofluorescence. These results suggested that the blocking effect on SE reactivity of these sera might be due to the presence of IgM and/or IgE antibodies reacting with the same epitope of the 5E antibody.
For several years there have been many arguments about the heterogeneity of anti-BMZ antibodies in BP sera (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .
The results in the present study clearly demonstrate the diversity ofepitopes that bind to anti-BMZ antibodies. However, as we have not found any molecules on immunoblotting other than 230 kD using our MAbs, the problem of the molecular heterogeneity of BP antigen must be solved by further investigation.
The human monoclonal anti-BMZ antibodies we established should be extremely valuable for various fields of investigation, such as immunopathology, cellular immunology, biochemistry, and molecular biology, and should be used to reveal the mechanisms of blister formation in BP. Further investigations using these MAbs are in progress in our laboratory.
